Effectiveness of influenza vaccine in children

Nof Saadi AlQarni, Alzain Mohammid Abdulla, Reham Hassan Abdulaziz Abdu, Basim Faiqe Noor Khan, Ahmed Hussain D. Alherz, Mohamed Ahmed M. Waznah, Mariam Naif W. Alotaibi, Wed Ziyad Alnajjar, Khaled Abdulaziz Alasous, Ahmed Khaled Almarri


Oseltamivir delivers modest clinical advantages to children with influenza when started within 48 hours of symptom beginning. Nevertheless, effectiveness and safety stay controversial. We conducted the current meta-analysis using a comprehensive search of EMBASE, MEDLINE, PubMed, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials till 15 February 2018 for randomized controlled trials of oseltamivir therapy in children. Four studies met the search criteria. Overall, oseltamivir treatment significantly reduced the duration of illness in the ITTI population (RMST difference, -18.2 hours; 95% CI, −32.2 to −0.6 hours). In trials that enrolled patients without asthma, the difference was larger (RMST difference −26.7 hours; 95% CI, −49.8 to −6.1 hours).Risk of otitis media was 34% lower in the ITTI population. Vomiting was the only adverse event with a significantly higher risk in the treatment group. Regardless of considerable heterogeneity in pediatric trials, we found that treatment with oseltamivir treatment started within 24 hours of symptom onset provides substantial benefits to children with influenza infection and lowered the risk of developing otitis media.



Oseltamivir, Influenza, Meta-Analysis, Infection, Children

Full Text:



Committee on Infectious Diseases. Policy statement—recommendations for the prevention and treatment of influenza in children, 2009–2010. Pediatrics. 2009;124(4):1216–26.

Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369-73.

Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The underrecognized burden of influenza in young children, N Engl J Med. 2006;355:31-40.

Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study, J Infect Dis. 2002;185:147-52.

Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012–2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis. 2015;211:1519–28.

Moscona A. Neuraminidase inhibitors for influenza, N Engl J Med. 2005;353:1363-73.

Kimberlin DW, Acosta EP, Prichard MN, Sánchez PJ, Ampofo K, Lang D, et al. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis. 2013;207:709–20.

Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:2545.

Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385:1729–37.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, 2007.

Higgins JP, Thompson SG, Deeks JJ. Altman DG. Measuring inconsistency in meta-analyses 2008.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986;7(3):177-88.

Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24:225–32.

Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–33.

Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Vahlberg T, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51:887–94.

Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14:109–18.

Gallaher WR. Towards a sane and rational approach to management of Influenza H1N1 2009. Virol J. 2009;6:51.

Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Vahlberg T, Ziegler T, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51(8):887-94.

Li CC, Wang L, Eng HW, You HW, Chang LS, Tang KS, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis. 2010;16:1265–72.

Ng S, Cowling BJ, Fang VJ, Chan KH, Ip DK, Cheng CK, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50:707–14.